Market Cool On Haoxi Health Technology Limited’s (NASDAQ:HAO) Earnings Pushing Shares 29% Lower

To the annoyance of some shareholders, Haoxi Health Technology Limited (NASDAQ:HAO) shares are down a considerable 29% in the last month, which continues a horrid run for the company. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 99% loss during that time.

Following the heavy fall in price, Haoxi Health Technology’s price-to-earnings (or “P/E”) ratio of 2.6x might make it look like a strong buy right now compared to the market in the United States, where around half of the companies have P/E ratios above 17x and even P/E’s above 30x are quite common. However, the P/E might be quite low for a reason and it requires further investigation to determine if it’s justified.

Our free stock report includes 4 warning signs investors should be aware of before investing in Haoxi Health Technology. Read for free now.

The earnings growth achieved at Haoxi Health Technology over the last year would be more than acceptable for most companies. One possibility is that the P/E is low because investors think this respectable earnings growth might actually underperform the broader market in the near future. If that doesn’t eventuate, then existing shareholders have reason to be optimistic about the future direction of the share price.

View our latest analysis for Haoxi Health Technology

Although there are no analyst estimates available for Haoxi Health Technology, take a look at this free data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.

Does Growth Match The Low P/E?

In order to justify its P/E ratio, Haoxi Health Technology would need to produce anemic growth that’s substantially trailing the market.

If we review the last year of earnings growth, the company posted a terrific increase of 20%. Pleasingly, EPS has also lifted 51% in aggregate from three years ago, thanks to the last 12 months of growth. Accordingly, shareholders would have probably welcomed those medium-term rates of earnings growth.

It’s interesting to note that the rest of the market is similarly expected to grow by 13% over the next year, which is fairly even with the company’s recent medium-term annualised growth rates.

In light of this, it’s peculiar that Haoxi Health Technology’s P/E sits below the majority of other companies. Apparently some shareholders are more bearish than recent times would indicate and have been accepting lower selling prices.

The Key Takeaway

Shares in Haoxi Health Technology have plummeted and its P/E is now low enough to touch the ground. Typically, we’d caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

We’ve established that Haoxi Health Technology currently trades on a lower than expected P/E since its recent three-year growth is in line with the wider market forecast. There could be some unobserved threats to earnings preventing the P/E ratio from matching the company’s performance. At least the risk of a price drop looks to be subdued if recent medium-term earnings trends continue, but investors seem to think future earnings could see some volatility.

Before you take the next step, you should know about the 4 warning signs for Haoxi Health Technology that we have uncovered.

Of course, you might also be able to find a better stock than Haoxi Health Technology. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.